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Meningeal infiltration of the spinal 
cord by non-classically activated B 
cells is associated with chronic 
disease course in a spontaneous B 
cell-dependent model of cns 
autoimmune disease
Amy K. Dang , Yodit Tesfagiorgis , Rajiv W. Jain , Heather C. Craig and Steven M. Kerfoot*
Department of Microbiology and Immunology, Schulich School of Medicine and Dentistry, Western University Canada, 
London, ON, Canada
We characterized B cell infiltration of the spinal cord in a B cell-dependent spontaneous 
model of central nervous system (CNS) autoimmunity that develops in a proportion of 
mice with mutant T and B cell receptors specific for myelin oligodendrocyte glycoprotein. 
We found that, while males are more likely to develop disease, females are more likely to 
have a chronic rather than monophasic disease course. B cell infiltration of the spinal cord 
was investigated by histology and FACs. CD4+ T cell infiltration was pervasive throughout 
the white and in some cases gray matter. B cells were almost exclusively restricted to the 
meninges, often in clusters reminiscent of those described in human multiple sclerosis. 
These clusters were typically found adjacent to white matter lesions and their presence 
was associated with a chronic disease course. Extensive investigation of these clusters 
by histology did not identify features of lymphoid follicles, including organization of T 
and B cells into separate zones, CD35+ follicular dendritic cells, or germinal centers. 
The majority of cluster B cells were IgD+ with little evidence of class switch. Consistent 
with this, B cells isolated from the spinal cord were of the naïve/memory CD38hi CD95lo 
phenotype. Nevertheless, they were CD62Llo and CD80hi compared to lymph node B 
cells suggesting that they were at least partly activated and primed to present antigen. 
Therefore, if meningeal B cells contribute to CNS pathology in autoimmunity, follicular 
differentiation is not necessary for the pathogenic mechanism.
Keywords: B cells, eae, demyelination, inflammation, meninges
introduction
The best evidence supports the hypothesis that multiple sclerosis (MS) is an autoimmune disease of 
the central nervous system (CNS) driven by immune cells targeting myelin antigens. The autoim-
mune response results in chronic inflammation of the CNS, demyelination, destruction of axons, and 
neurodegeneration over an extended period of time (1, 2). The presence of infiltrating immune cells 
in MS CNS tissues, including potentially myelin-specific T and B cells, supports a primary immune 
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etiology for disease (3–6), as do studies that have identified genes 
associated with the immune system, immune regulation, and 
antigen presentation as the primary genetic risk factors for MS 
(7). Deliberate induction of myelin-targeting autoimmunity in 
animal models results in CNS inflammation and pathology that 
recapitulates some features of human MS, although the degree to 
which these models resemble human disease varies depending 
on how autoimmunity is induced and on the species or strain of 
animal used (8–10).
Outside of the laboratory, the vast majority of immune 
responses incorporate antigen targeting by multiple subpopula-
tions of both T and B cells. However, in recent decades, research 
interest has focused heavily on CD4+ T cells and this is particularly 
true of MS research. Considerable advances in our understand-
ing of how B cells collaborate with CD4+ T cells during the ini-
tiation and development of a response highlight the importance 
of understanding immune responses as a whole. When both T 
and B cells are involved in target recognition, germinal center 
(GC) formation is the typical result. GCs are the source for long 
lived, high affinity B cell and antibody responses fundamental 
to normal, complex protective, and pathogenic immunity (11). 
While best known for their role in antibody production, it is 
becoming increasingly apparent that B cells are also important 
regulators and modulators of the immune response through the 
production of cytokines (12, 13) and presentation of antigen to 
T cells (14). As antigen-presenting cells (APCs), B cells very effi-
ciently take up antigen that binds to their specific B cell receptor 
(BCR) and process it for presentation to T cells. The resulting 
“cognate” interactions between T and B cells specific for the same 
or physically linked antigen are foundational to the development 
of most complex immune responses (15, 16), almost certainly 
including those underlying organ-specific autoimmune diseases 
like MS (4).
Considerable evidence supports an important role for B cells 
in addition to T cells in driving MS pathology. The presence of 
antibodies in the cerebrospinal fluid (CSF) and B cells in the 
CNS infiltrate has long been recognized as features of disease 
(4, 5). More recently, targeted depletion of CD20-expressing B 
cells using humanized anti-CD20 antibodies was shown to very 
effectively reduce inflammatory signs and relapses in MS (17). 
This ignited interest in B cells as therapeutic targets. However, 
a more recent trial of a soluble recombinant version of the 
cytokine receptor TACI (TACI-Fc), which depletes B cells 
through the inhibition of the cytokines BAFF and APRIL, was 
halted early due to indications that treatment increased relapse 
rate (18). Anti-CD20 and TACI-Fc deplete B cells through very 
different mechanisms and target different subsets of cells (19). 
CD20 is not expressed by antibody-producing plasma cells and 
therapeutic benefit of anti-CD20 was observed well prior to 
any reduction in antibody levels. By contrast, TACI-Fc does 
target plasma cells in addition to mature B cells. Further, as 
both T cells and neurons express receptors for BAFF (20, 21), 
the effects of this drug likely extend well beyond B cell deple-
tion. Therefore, while antibodies may contribute to pathology 
(1), the primary B cell contribution to MS is through some 
other mechanism(s), perhaps via APC function or cytokine 
modulation of the autoimmune response. Furthermore, the 
effectiveness of B cell depletion via anti-CD20 (17) suggests 
that their pathogenic role is ongoing and drives chronic 
disease. The lack of benefit and perhaps pathogenic effects of 
TACI-Fc confuses the issue, and highlights the need to identify 
pathogenic and protective B cell subpopulations and their roles 
in CNS autoimmunity.
It is also not clear where, anatomically, B cells exert their 
pathogenic function. There has been considerable recent interest 
in clusters of B and T cells observed in the meninges in post-
mortem studies of MS brains, often in direct association with 
demyelinating lesions (3, 6, 22). Some studies have focused on 
the potential similarity of these structures to secondary lymphoid 
organs, suggesting that they may perform similar functions in 
propagating immune responses from within the inflamed CNS 
(23, 24). Understanding the pathogenic contributions of B cells 
and the role played by meningeal clusters to ongoing disease will 
require models that appropriately recapitulate a complex anti-
myelin immune response.
Animal models with induced anti-myelin autoimmunity are 
referred to by the umbrella term “experimental autoimmune 
encephalomyelitis” (EAE). Currently, the most commonly used 
versions of this model are induced through immunization with 
short peptides mimicking dominant CD4+ T cell epitopes derived 
from myelin protein antigens. By their design, these models 
severely limit the involvement of other lymphocytes, including 
B cells that would normally participate in antigen targeting. 
Immunization with larger protein antigens can overcome this 
limitation (25). Alternatively, B cells may contribute to several 
non-immunization-based models. CNS autoimmunity can 
develop “spontaneously” (sEAE) in a proportion of mice with 
enhanced anti-myelin activity due to expression of mutant 
antigen-specific receptors (26–28). In most cases, enhanced anti-
myelin immunity is restricted to T cells. However, two groups 
(29, 30) independently reported that disease occurs with much 
greater incidence in mice expressing both a transgenic T cell 
receptor (TCR) specific for myelin oligodendrocyte glycoprotein 
(MOG)35–55 peptide (26) and a BCR heavy chain knock-in mice 
that, when paired with an appropriate light chain, also confers 
specificity for MOG protein on ~20% of B cells (31). This model, 
with predetermined B as well as T cell recognition of the myelin 
autoantigen, may therefore be valuable for investigations of the 
B cell collaboration with autoimmune T cells to promote CNS 
autoimmune disease.
Here, we characterize B cells participating in spontaneous 
CNS autoimmune disease in 2D2 IgHMOG mice. We observe that 
sEAE can follow either a monophasic or chronic disease course 
and that this correlates with ongoing inflammation in the spinal 
cord and with formation of meningeal clusters of T and B cells in 
particular. However, we found little evidence that the B cells in 
meningeal clusters are activated in a conventional sense. Finally, 
only in a very rare case did we find any evidence of development 
of follicular features in meningeal clusters, indicating that if clus-
ters do contribute to ongoing pathology in CNS autoimmunity, 
the relatively unorganized form must represent the minimum 
requirement for disease.
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Materials and Methods
Mice
Wild type C57Bl/6 and 2D2 TCR transgenic (26) mice were 
purchased from Jackson Laboratories. IgHMOG MOG-specific 
BCR knock-in mice (32) were received as a gift from Dr. 
Hartmut Wekerle. Genotyping was accomplished using the fol-
lowing primers: 2D2: f-GCG GCC GCA ATT CCC AGA GAC 
ATC CCT CC, r-CCC GGG CAA GGC TCA GCC ATG CTC 
CTG; IgHMOG: f-GGA TTG CAC GCA GGT TCT CCG, r-CCG 
GCC ACA GTC GAT GAA TCC. All mice were housed under 
specific pathogen-free conditions at the West Valley Barrier 
Facility at Western University Canada. Animal protocols 
(#2011-047) were approved by the Western University Animal 
Use Subcommittee.
antibodies for Flow cytometry and histology
The following antibodies were purchased from BD Biosciences: 
anti-CD4-V450 (RM4-5), anti-CD45R-V450 (RA3-6B2), anti-
CD45R-APC-Cy7 (RA3-6B2), anti-CD45R-A647 (RA3-6B2), 
anti-CD138-BV421 (281-2), anti-CD19-BV711 (1D3), 
anti-CD95-PE-Cy7 (Jo2), anti-Bcl6-A647 (K112-91), anti-
IgG1-APC (A85-1), anti-CD62L-A700 (MEL-14), anti-CD35-
biotin (8C12), anti-CD49D (R1-2), anti-CD62P (RB40.34), 
anti-IgM-APC (II/41), and anti-CD80-PE (16-10A1). The follow-
ing antibodies were purchased from BioLegend: anti-CD4-A647 
(RM4-5), anti-CD3e-FITC (145-2C11), and anti-rabbit DyLight 
649 (Poly4064). The following antibodies were purchased from 
eBioscience: anti-CD4-PE-Cy5 (RM4-5), anti-PNAd-A488 
(MECA-79), anti-CD38-PE (90), anti-IgM-PE-Cy5 (II/41), 
anti-IgD-APC (11-26c), anti-IgD eF450 (11-26c), anti-CD279-
Biotin (RMP1-30), anti-CD273-Biotin (TY25), anti-F4/80-
Biotin (BM8), Streptavidin-APC-eF780, and Streptavidin-APC. 
Anti-Ki-67 (SP6) unconjugated was purchased from Thermo 
Scientific. FluoroMyelin Red for myelin staining was purchased 
from Invitrogen.
spontaneous 2D2 ighMOg eae Model
2D2+/− IgHMOG+/− double mutant mice were generated as the F1 
generation of 2D2+/− mice crossed with IgHMOG+/+ mice. Where 
indicated, some mice received a single i.v. injection of 250  ng 
pertussis toxin (PTX – List Biological Laboratories, Inc.) between 
31 and 33 days of age. Clinical disease was monitored daily and 
was scored as follows: 0, no clinical signs; 1, tail paralysis; 2, tail 
paralysis and hind limb weakness; 3, hind limb paralysis; and 
4, complete hind limb paralysis and front limb weakness. Half 
points were given for intermediate scores.
Flow cytometry
Flow cytometry analysis of T cells and B cells harvested from 
mouse lymph nodes and spinal cords was performed, as previ-
ously described (25). Briefly, spinal cord and lymph nodes, 
including inguinal, axillary, and cervical lymph nodes, were 
harvested from mice after perfusion with ice cold PBS. Individual 
spinal cords were additionally dissociated through a wire mesh 
after which myelin was removed using a Percoll (GE Healthcare 
Life Sciences) gradient. Leukocytes were collected at the 37/90% 
Percoll interface.
Both lymph node and isolated spinal cord cell suspensions 
were blocked with an anti-Fc-γ receptor (CD16/32 2.4G2) in 
PBS containing 1% FBS before further incubation with the listed 
combination of staining antibodies. Dead cells were excluded 
by staining with the Fixable Viability Dye eFluor506 (eBiosci-
ence). Flow cytometry was performed on a LSRII cytometer (BD 
Immunocytometry Systems) and analyzed with FlowJo software 
(Treestar).
immunofluorescent histology
Spinal cords and lymph nodes were extracted from mice and pre-
pared, as previously described (25). Briefly, whole lymph nodes 
and spinal cords were fixed in periodate–lysine–paraformalde-
hyde (PLP) and subsequently passed through sucrose gradients to 
protect from freezing artifacts. Lymph nodes were frozen whole 
in OCT (TissueTek) media. Spinal cords were cut into five to nine 
evenly spaced pieces and arranged in order prior to freezing in 
OCT. Serial cryostat sections (7 μm) were blocked in PBS con-
taining 1% Bovine Serum Albumin, 0.1% Tween-20, and 10% rat 
serum before proceeding with staining. Sections were mounted 
with ProLong Gold Antifade Reagent (Invitrogen) and stored at 
−20°C. Tiled images of whole spinal cord sections (20×) were 
imaged using DM5500B fluorescence microscope (Leica).
image and statistical analyses
The size of meningeal clusters in images of diseased spinal cords 
was analyzed using ImageJ software. PRISM software was used for 
all statistical analysis. Unless otherwise stated, single comparisons 
were performed using a Student’s t-test and multiple comparisons 
were performed by ANOVA followed by a Tukey post hoc test.
results
Disease incidence in 2D2 ighMOg Double Mutant 
Mice
We followed mice bearing mutant TCR and BCR specific for 
MOG autoantigen for the development of CNS autoimmune dis-
ease. Mice demonstrating overt signs of physical disability were 
defined as “sick.” Consistent with the previous descriptions (29, 30, 
33), a proportion of unmanipulated 2D2+/− IgHMOG+/+ mice (here 
after described as 2D2 IgHMOG) developed sEAE (Figure  1A). 
No disease was observed in either 2D2 (TCR) or IgHMOG (BCR) 
single mutant mice (Not Shown); it is clearly demonstrating that 
antigen recognition by both T and B cells contributes to disease 
development in double mutant mice. Interestingly, males were 
significantly more likely to develop disease than females, although 
there was no difference in the time of onset (Table 1). Although 
previous studies did not note gender differences, the incidence 
data presented by Krishnamoorthy et al. (30) suggest a similar 
trend in male bias.
Overall incidence was highly variable over the study period. 
Initially, 39% of unmanipulated mice developed signs of disease 
(Figure 1A, Timepoint 1), but over ~2 years of study incidence 
fell to 0% (Timepoint 2) but later rose to nearly 100% incidence 
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(Timepoint 3). Season has previously been identified as a fac-
tor contributing to susceptibility to EAE in a different induced 
model (34), but did not explain the variance observed in the case 
of our 2D2 IgHMOG colony. We also excluded obvious changes in 
environmental factors, such as food or alterations in animal care. 
Differences in animal housing, largely attributed to differences 
in microbial exposure, are well known to impact EAE models 
and spontaneous models, in particular, both between institutions 
and within the same colony (27, 35). We did not investigate com-
mensal bacteria in our own studies, but unexplained changes 
in microbiota over time may be the underlying reason for the 
dramatic shifts in incidence we observed within our colony. 
Nevertheless, this suggests that, like human MS, spontaneous 
CNS autoimmune disease in 2D2 IgHMOG mice is variable and 
influenced by environmental factors.
Pertussis toxin (PTX) is commonly used in the induction 
of several models of immunization-induced EAE, particularly 
in C57Bl/6 mice. While the disease-promoting mechanism(s) 
are not entirely clear (36–38), PTX represents an antigen non-
specific pathway to promote disease. Indeed, PTX was shown to 
increase incidence in a similar model of otherwise spontaneous 
CNS autoimmunity that develops in mice expressing a transgenic 
TCR to myelin basic protein (27). In our hands, we similarly 
found that a single i.v. injection of 250 ng PTX was sufficient to 
significantly increase disease incidence in 2D2 IgHMOG mice dur-
ing periods of lower disease incidence (<80%) (Figures 1B,C). 
Disease in PTX-treated mice was otherwise indistinguishable 
from that in mice that did not receive PTX (not shown). The 
mechanism by which it promotes disease induction is not yet 
clear, but we (37) and others (36, 39) have shown that PTX has 
innate immunomodulatory effects. Therefore, PTX may act as a 
surrogate for environmental factors that promote development of 
CNS autoimmune disease.
2D2 ighMOg Mice Develop either Monophasic or 
chronic Disease
2D2 IgHMOG mice were evaluated daily for disease severity. Of 
those that showed signs of disease (defined as “sick”), the majority 
of mice had severe disability of the tail, hindlimbs, and partial 
involvement of the forelimbs, reminiscent of other EAE models 
and consistent with previous descriptions of this model (29, 30). 
Unlike for disease incidence (see above), there was no differ-
ence between males and females in maximum disease severity 
(Table 1). We observed that disease typically followed one of two 
courses; after the initial acute phase some mice largely recovered 
with little evidence of ongoing disability while others showed 
little sign of recovery. Therefore, we grouped mice that survived 
past 21  days post disease onset (i.e., that had not been used 
experimentally or been euthanized early due to severe disease) 
into one of two groups based on their final disease status: (1) 
chronic  –  mice with no more than 1 point recovery after the 
acute phase as determined by the standard 5 point score system, 
and 2) Monophasic  –  mice that recovered at least 1 point on 
the severity scale and had a final score <2 (Figure 2). Further 
evaluation of these populations showed that while the timing of 
disease onset was not different between them, the chronic group 
attained a significantly higher maximum disease score (Table 2). 
FigUre 1 | incidence of spontaneous cns autoimmune disease 
(seae) in 2D2 ighMOg mice. (a) Disease onset curves for three 
representative sequential 4- to 6-month time-periods (Timepoint 1, 2, 
and 3) selected from the ~2-year period of study. The percent of mice in 
each group to demonstrate signs of disability as determined by the 
disease scoring system (see Materials and Methods) is shown (% Sick) 
(B,c) PTX administration increases disease incidence. (B) Single 
injections of 250 ng PTX i.v. were administered to ~32 days old 2D2 
IgHMOG mice, which were subsequently followed for onset of disease 
compared to unmanipulated mice. (c) Fraction of diseased mice in 
PTX-untreated and -treated mice, restricted to times when the overall 
incidence was below 80%. Significantly more PTX-treated mice 
developed disease as determined by Chi-square analysis (p = 0.0003, 
df = 13.13,1).
TaBle 2 | Monophasic and chronic disease profiles in 2D2 ighMOg mice.
n= Day onset seM Max score seM
Monophasic 42 38.2 (±0.62) 2.26 (±0.117)
Chronic 30 35.8 (±1.47)n.s. 2.98 (±0.106)***
***p < 0.001.
n.s., not significant.
FigUre 2 | seae in 2D2 ighMOg mice can follow a monophasic or chronic disease course. (a) 2D2 IgHMOG mice were allowed to develop CNS autoimmune 
disease and severity was evaluated daily. Mice that developed signs of CNS autoimmune disease for at least 21 days (excluding mice that had been used 
experimentally or were euthanized prior to 21 days) were divided into “monophasic” or “chronic” categories based on the following criteria: chronic – no more than 1 
point recovery after the acute phase as determined by the standard 5 point score system. Monophasic – recovery of at least 1 point on the severity scale and a final 
score <2. (B) Compared to male mice, a greater proportion of female mice develop chronic disease as determined by Chi-square analysis (p = 0.0004, df 12.65,1).
TaBle 1 | Disease profiles in 2D2 ighMOg mice by gender.
n= sick incidence Day onset seM Max score seM
Male 154 95 61.7% 36.7 (±0.52) 2.55 (±0.107)
Female 137 68* 49.6% 36.6 (±0.68)n.s. 2.43 (±0.143)n.s.
*p = 0.0387, df = 4.275,1 by Chi squared analysis. Note that mice that did not develop disease were not included in analysis of onset and severity.
n.s., not significant.
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This indicates that while the populations were separated into the 
chronic or monophasic groups based principally on their status 
at the end of the study, the differences between groups manifested 
themselves earlier in the acute phase of disease (Figure  2A). 
Interestingly, while males were more likely to develop disease 
(see above), females were more likely to have a chronic disease 
course (Figure 2B).
characterization of the B cell response in 2D2 
ighMOg Mice
Previous studies employing the 2D2 IgHMOG model focused pri-
marily on T cell activation (29, 30, 33) and information about B 
cell activation in this or other spontaneous models is very limited. 
Immune responses that incorporate both T and B cell recogni-
tion of antigen typically result in a GC response. Consistent with 
this, significantly more CD95hi CD38lo GC B cells were present 
in lymph nodes harvested from sick 2D2 IgHMOG mice (~3 weeks 
post onset) compared to wild type or age-matched 2D2 IgHMOG 
that did not develop sEAE (Figures  3A,B). It should be noted 
that, with disease progression and severity, we observed lymph 
node atrophy and in some cases little remaining GC response 
could be detected (not shown).
evaluation of spinal cord Pathology in 2D2 
ighMOg Mice
2D2 IgHMOG mice were sacrificed for histological evaluation of 
CNS pathology. No evidence of pathology or inflammation was 
evident in the CNS of wild type mice (Figure 4A) or 2D2 IgHMOG 
mice that did not develop disease (not shown). Consistent with 
previous descriptions of this model (29, 30), there was little 
evidence of inflammation in the brains of 2D2 IgHMOG mice that 
developed disease (not shown). By contrast, extensive and pro-
found pathology was observed in the spinal cord. Evaluation of 
tissue harvested from mice in the acute phase of disease (<11 days 
post onset) revealed that extensive infiltration by CD4+ T cells 
(Figure 4, compare Figure 4A – wild type to Figure 4B – acute 
2D2 IgHMOG) was associated with regions of reduced myelin stain-
ing (Figures 4B,C, inset box ii, middle) and F4/80+ macrophage/
activated microglia (Figure 4C, bottom). CD4+ T cells were also 
observed in the gray matter in some mice and in these cases 
myelin staining of the gray matter was often altered compared to 
healthy mice (Figure 4C top, inset box i).
B cell infiltration of the spinal cord was almost exclusively 
restricted to the meninges although rare cells could be found in 
the white matter lesions. Meningeal B cells often formed clusters 
in close association with CD4+ T cells (Figures 4B,C, inset box 
ii) reminiscent of lymphoid clusters described in human MS 
tissue (3, 6, 22). Similar clusters were also reported in other 
FigUre 3 | characterization of B cells in the lymph nodes and spinal cords of 2D2 ighMOg mice with seae. (a) Lymph nodes and spinal cords were 
harvested from healthy wild type mice as well as 2D2 IgHMOG mice that had either developed disease (sick – 20–30 days post onset) or not (healthy – age matched). 
Cells were prepared and analyzed by FACS. CD45R+ cells were first selected. An example of the gating strategy to identify Plasma cells [(a) – left] and B cells with a 
GC phenotype [(a) – right] from the CD45R+ pool is shown for lymph node and spinal cord cells isolated from a single sick mouse. (B) Quantification of CD95hi 
CD38lo germinal center B cells in the lymph nodes of wild type and healthy or sick 2D2 IgHMOG mice. Each symbol represents an individual mouse. *p < 0.05. (c) 
Comparison of CD62L (left) and CD80 (right) expression by CD45R+ CD19+ CD138− B cells isolated from lymph nodes or the CNS of the same mouse. Each symbol 
represents an individual sick mouse. ***p < 0.001 as determined by paired Student’s t-test. One representative of two experiments shown.
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investigations of this model (29, 30, 33), indicating that they are 
a consistent feature of disease in 2D2 IgHMOG mice. These clus-
ters were very often in direct association with regions of white 
matter demyelination and CD4+ T cell infiltration (Figure 4B). 
Pathology was not restricted to any particular region of the spinal 
cord as in some cases the entire spinal cord was involved, while 
in others inflammation was restricted to either distal (lumbar) or 
proximal (cervical) regions (not shown).
B cell infiltration of the spinal cord is 
associated with chronic Disease
We next evaluated spinal cord pathology later in disease 
(>20 days post disease onset) in mice with either a chronic or 
monophasic disease course (as defined above). White matter 
pathology in monophasic mice was very limited, in that there 
was little CD4+ T cell infiltration or demyelination (Figure 5A). 
By contrast, ongoing white and gray matter inflammation by 
CD4+ T cells and white matter demyelination was clearly evident 
in mice with chronic disease (Figure  5B) demonstrating that 
continued disability in these mice reflects active and ongoing 
inflammation, rather than permanent injury incurred during 
the initial attack. Large meningeal clusters containing T and 
B cells were also common in these mice. Nevertheless, despite 
reduced white matter involvement, small meningeal clusters 
were sometimes also present in monophasic mice (Figure 5A). 
However, subsequent analysis confirmed that meningeal clusters 
were both more numerous (Figure 5C) and larger (Figure 5D) 
in chronic vs. monophasic mice. Further, independent of disease 
course classification the size of meningeal clusters correlated with 
disease severity (Figure 5E). This, combined with the common 
spatial association between clusters and underlying regions of 
demyelination, suggests that these structures may contribute to 
ongoing chronic CNS autoimmune disease in 2D2 IgHMOG mice.
characterization of B cells in Meningeal 
clusters
To begin to dissect the role that B cells play in spinal cord 
pathology in sEAE, we evaluated the activation phenotype of 
FigUre 4 | evaluation of spinal cord pathology in 2D2 ighMOg mice. Mice were sacrificed in the acute phase of disease (<11 days post onset) and spinal cord 
pathology was evaluated by immunofluorescent histology. Sections were stained for myelin and invading CD4+ T cells and B220+ B cells. [(a) – wild type health 
control, (B) – 2D2 IgHMOG acute disease]. Infiltrating T cells (open triangles) were evident in the gray matter of diseased mice [see (B) inset box i, shown at higher 
magnification in (c), top panel]. Clusters containing B220+ B cells and CD4+ T cells (closed triangles) were clearly apparent in the meninges of diseased mice, while 
no B cells were found in healthy spinal cords [compare (a) with (B)]. Meningeal clusters were often adjacent to areas of demyelination and CD4+ T cell infiltration of 
the white matter (open triangles). Ongoing parenchymal invasion by T cells and macrophages/activated microglia were clearly evident, associated with regions of 
demyelination [open triangles, see enlarged image and serial section stained with F4/80, inset box ii, (c)]. Representative images shown (n = 5 wt, n = 5 acute 
phase 2D2 IgHMOG, minimum three sections taken from different regions of each spinal cord). Scale bars represent 200 μm.
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infiltrating B cells. FACS analysis of lymphocytes isolated from 
spinal cords revealed that B cells are almost exclusively CD38hi 
CD95lo, consistent with naïve or memory lymph node B cells 
(Figure 3A). However, compared to lymph node B cells with a 
similar CD38hi CD95lo phenotype, spinal cord B cells had sig-
nificantly lower expression of CD62L and higher expression of 
CD80 (Figure 3C), indicating at least some level of non-classical 
activation, perhaps to present antigen. Cluster B cells were further 
characterized by histological examination of spinal cord tissue. 
We focused on spinal cords from chronic mice (see above) with 
evidence of ongoing disease activity. Consistent with a potential 
role for B cells in presenting antigen to T cells in clusters, T and 
B cells were found in close physical association with each other 
(Figures  6A,B). Subsequent staining confirmed that T cells in 
clusters were almost exclusively CD4+ T cells. However, we 
were surprised to find that CD8+ T cells were minor yet com-
mon component of the T cell infiltrate of white and gray matter 
(Figure 6A). This was not the case in the acute phase of disease 
(not shown). Although CD8+ T cells are known to infiltrate the 
CNS in human MS and contribute to some animal models of CNS 
autoimmunity (2, 35), we did not expect their presence in the 2D2 
IgHMOG model as the 2D2 TCR is derived from an MHC class 
II-restricted CD4+ T cell (26). However, CD8+ T cells were shown 
to infiltrate the CNS and participate in pathology in a similar 
model that makes use of a different MOG35-55-specific TCR on 
the NOD background. Although the TCR in this model was 
similarly derived from a CD4+ T cell, CD8+ T cells were found to 
express the transgenic TCR and recognize the MOG35–55 peptide 
presented on MHC class I (40).
We further investigated cluster B cells for evidence of activa-
tion. While Ki67+ cells were detectable within clusters as well as 
in the white matter, very few of them were co-stained with B cell 
markers (Figure 6B). Instead, the large majority of proliferat-
ing Ki67+ cells were T cells (not shown). CD138+ Plasma cells 
were not apparent in clusters (Figure  6C). Finally, cluster B 
cells were investigated for evidence of class switch. Virtually, 
all B cells expressed IgD (Figure 6D) and IgM, but not IgG1 
(not shown).
FigUre 5 | B cell infiltration of the spinal cord is associated with chronic disease and increased disease severity. At study endpoints (~4 weeks post 
disease onset), spinal cords were harvested for evaluation of pathology by immunofluorescence histology. Spinal cords from mice deemed to have either a 
“Monophasic” (a) or “Chonic” (B) disease course (as defined in Figure 2) were evaluated for demyelination, CD4+ T cell infiltration and meningeal cluster formation. 
Solid arrowheads indicate meningeal clusters. Open arrowheads indicate regions of white matter demyelination and infiltration by CD4+ cells. Scale bars represent 
200 μm. The number of meningeal clusters per section (c) and cluster area (D) was evaluated using Image J software. Three sections from different regions of the 
spinal cord were evaluated from each mouse. **p < 0.01 as determined by Student’s t-test. Each symbol represents the average value per section from an individual 
mouse. (e) Cluster size was correlated with average disease score (as a measure of overall disease severity) for each individual mouse included in the study. Each 
symbol represents an individual mouse. A two tailed Pearson r test was performed to test for correlation.
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It has been suggested that meningeal clusters in the CNS of MS 
patients may function as the so-called tertiary lymphoid tissues 
that recapitulate the structure and function of secondary lym-
phoid organs, such as lymph nodes and spleen (22). We therefore 
evaluated meningeal clusters in chronic 2D2 IgHMOG mice for fea-
tures of lymphoid follicles. With the exception of a single cluster 
in one mouse from the chronic group (Figure 6E), there was no 
evidence that T and B cells were organized into separate zones 
as occurs in lymphoid tissue (see Figures 4B, C, 5 and 6A–D for 
examples). Neither evidence of CD35+ follicular dendritic cells 
(FDCs) (Figure 6F) nor Bcl-6+ staining (GC B cells or T follicular 
helper Tfh cells) (not shown) was evident in any cluster that we 
examined. Finally, while some evidence of PNAd staining was 
apparent in the single cluster with evidence of T and B cell organi-
zation (Figure 6F), perhaps indicating development of special-
ized high endothelial venules, PNAd staining was not evident in 
any other cluster that we examined (not shown). Therefore, while 
it is possible that given sufficient time a proportion of meningeal 
clusters may attain some features of organized lymphoid tissue, 
the majority of clusters remain largely unorganized. If, as their 
association with demyelinating regions suggests, these clusters 
do contribute to the pathology of CNS autoimmunity, the less 
organized form must represent the minimum requirement for the 
pathogenic mechanism.
Discussion
Here, we characterize a spontaneous model of CNS autoim-
munity that depends on both T and B cell recognition of the 
myelin autoantigen. We are aware of only three previously 
published studies using this 2D2 IgHMOG model. The original 
descriptions came from independent studies from Bettelli et al. 
(29) and Krishnamoorthy et al. (30) that focused principally on 
characterizing T cell activation as well as lesion distribution, 
which they found to be limited to the optic nerve and spinal 
cord. A third study made creative use of a version of this model 
 FigUre 6 | evaluation of meningeal clusters in spinal cords from 2D2 ighMOg mice with chronic seae. Serial sections of spinal cord tissue from mice 
determined to have chronic disease (see Figure 2) were stained by immunofluorescence to characterize infiltrating immune cells. Images of one representative 
cluster from a single mouse (n = 7) are shown (a–e). Scale bars represent 100 μm. (a) CD3+ CD8+ T cells were a common but minor component of the white 
matter infiltrate (open arrowheads), but only very rarely in meningeal clusters. (B) CD4+ cell infiltration into a region of demyelination adjacent to a meningeal cluster 
composed of B220+ B cells and CD4+ T cells. Inset box indicates the magnified region shown in subsequent serial sections. (c) Ki67+ cells in cell cycle were evident 
in meningeal clusters and in the affected white matter. The large majority of Ki67+ cells did not co-stain with B220 (example – closed arrowhead), with only very rare 
exceptions (open circle). (D) Little to no evidence of CD138+ plasma cells was observed in association with meningeal clusters. (e) Nearly, all B220+ B cells in 
meningeal clusters co-stained with IgD and therefore not class-switched (gray-scale of IgD channel alone shown on right). (F) Evaluation of meningeal clusters for 
evidence of features of lymphoid follicles. (Top) images of the single cluster from a 2D2 IgHMOG mouse with chronic disease to show evidence of T and B cell 
organization into different separate regions (left, top – compare to B cell follicle and T cell zone separation in a healthy naïve lymph node, bottom) and differentiation 
of specialized high endothelial venules (middle top – compared to extensive PNAd staining in the lymph node, bottom). Little to no evidence of CD35+ follicular 
dendritic cells (right, top – compared to extensive follicular staining in the lymph node, bottom) was apparent in this meningeal cluster. For each stain listed above, 
between four and seven individual mice with chronic disease were evaluated, choosing sections with the most developed clusters.
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to demonstrate that antibody production by MOG-specific 
B cells was not important to disease initiation, which instead 
was linked to antigen presentation by B cells to T cells (33). As 
discussed in more detail below, our findings presented here are 
largely consistent with these previous reports. We extend these 
studies by focusing on the B cell response and on character-
izing infiltrating B cells and meningeal clusters in the diseased 
spinal cord.
The primary goal of our study was to characterize the B cell 
response in this B-cell-dependent model of CNS autoimmune 
disease. As expected, measurable GC responses were detected in 
lymph nodes from sick mice, although this was not true in all 
cases due to lymph node atrophy. Nevertheless, a GC response 
driven by interactions between MOG-specific T and B cells is pre-
sumably the mechanism for B cell-dependent disease initiation, 
as B cell presentation of antigen has been shown to be essential in 
a similar B cell-dependent mouse model (33). Of greater interest 
to therapeutic intervention in autoimmunity is the potential role 
of B cells in propagating ongoing disease, which may occur from 
within the inflamed CNS. With the exception of the involvement 
of CD8+ T cells, which were relatively common infiltrates of the 
spinal cord parenchyma in chronic but not acute disease, inflam-
mation and pathology was qualitatively similar over the course 
of active disease. We observed extensive B cell infiltration of the 
meninges wherever white matter pathology was apparent, often 
forming clusters with CD4+ T cells. By contrast, white matter 
pathology was largely absent in mice that had recovered from 
monophasic disease. It is not clear if this reflects myelin repair 
or if extensive demyelination did not occur in these mice and 
disability was a reflection of inflammation, rather than actual 
tissue destruction.
Contrary to our initial expectations, B cells in meningeal 
clusters showed little indication of activation, with no evidence 
of class switch and little proliferation compared to infiltrating 
CD4+ T cells. By FACS, spinal cord B cells were CD38hi CD95lo, 
consistent with naïve or memory cells, although elevated CD80 
in particular suggests a degree of activation. Further investiga-
tion will be required to determine if B cells upregulate CD80 once 
in the meninges or if CD80hi B cells are selectively recruited. It 
should be noted that B cell follicles in secondary lymphoid 
tissues are largely populated by naïve B cells, and therefore an 
unactivated phenotype would be expected if meningeal clus-
ters do indeed represent lymphoid structures. However, with 
the possible exception of the single cluster in a mouse with 
chronic disease described above, we did not observed any other 
evidence of typical follicular features in the meningeal clusters 
that formed in sick 2D2 IgHMOG mice. We previously observed 
similar clusters in a model of EAE induced by immunization with 
a protein antigen based on mouse MOG (25). Again, there was no 
evidence of follicular differentiation in these clusters. Together, 
these models suggest that cluster formation is common in models 
that incorporate B cell recognition of the autoantigen. This is not 
an absolute requirement, however, as small clusters could still 
form in mice with mutant BCR incapable of recognizing MOG 
or in mice immunized with the standard short MOG35–55 peptide 
(25). White matter demyelination and inflammation were much 
reduced compared to what we observed in either MOG protein-
induced disease or in sick 2D2 IgHMOG mice, which also feature 
greater meningeal B cell infiltration.
Models of CNS autoimmunity that incorporate target rec-
ognition by more than just CD4+ T cells, such as 2D2 IgHMOG 
mice or EAE models induced with protein antigen, represent 
significant improvements over peptide-induced models that are 
used most commonly today as they allow for a more normal and 
complex response. Responses to “real” antigens recruit multiple 
immune targeting and effector processes. Nevertheless, it is 
not clear that these models more accurately represent human 
MS. Focusing specifically on investigations of infiltrating B 
cells in MS, lineage analysis suggest that B cells isolated from 
CNS represent a population derived from the GC response 
and subsequently selected from the peripheral pool (4, 41, 42). 
FACS studies suggest that CSF B cells are enriched for CD27+ 
cells (4, 43, 44), which in humans is considered a marker of 
memory. Therefore, these studies suggest that at least some B 
cells in human disease were previously activated. As there is no 
equivalent memory marker in mice, it is not currently possible 
to directly compare these observations to our own of the 2D2 
IgHMOG model.
Histological studies of human post-mortem tissue have 
been inconsistent in finding meningeal clusters (3, 6, 45–48). 
When clusters have been observed (3, 6, 45), more examples 
of follicular differentiation were reported than we observed in 
our mouse models [here and in Ref. (25)]. Nevertheless, our 
observations suggest that, given time, it is possible that menin-
geal clusters can attain at least some features of true follicles. 
Human studies were performed on tissues from patients who 
had disease for many years and in most cases decades (22), and 
despite their focus on the most follicle-like structures, it is clear 
that most meningeal clusters in MS remained largely unorgan-
ized (22, 23), consistent with our observations in both mouse 
models. Furthermore, human studies were almost exclusively 
of progressive disease, where neurodegeneration occurs even 
though there is less evidence of active inflammation (2). It is 
not clear that these observations are relevant to the earlier active 
inflammatory stage of disease that is likely a better correlate to 
EAE. The rarity of tissue from this earlier stage of disease and 
of spinal cord tissue will make direct comparison very difficult. 
Nevertheless, as the best evidence supports the hypothesis that 
MS is an autoimmune disease targeting myelin antigens, holis-
tic models of CNS autoimmune disease that more completely 
involve the immune system have the best chance of revealing 
important fundamental pathogenic B cell mechanisms that 
drive ongoing disease.
The apparent contradictory effects of B cell depletion by anti-
CD20 (17) vs. TACI-Fc (18) in human MS highlights the urgent 
need to better understand the complex biology of these cells in 
autoimmune disease and the immune response in general. Both 
anti-CD20 and TACI-Fc target IL-10-producing Breg cells (19, 
49). However, they have very different activity on plasma cells 
and therefore antibody production (19), as well as T cell biology 
(20). There are likely additional B cell subsets with differential 
susceptibility to depletion by each reagent. Indeed, IgM+ 
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memory B cells are more dependent on BAFF and therefore to 
depletion by TACI-Fc than class-switched memory cells (50). 
Anatomical location may also affect susceptibility to depletion 
by either reagent. Work to decipher this will have to rely heavily 
on models, such as the 2D2 IgHMOG mice, as in human patients 
usually only the circulating and more rarely CSF pools can 
be accessed. Our models suggest that antigen-specific B cells 
contribute to disease but that, unexpectedly, the B cell infiltrate 
in the CNS are not activated in a way that we would expect 
based on studies of antigen-specific activation in lymphatic tis-
sue. Further work will be required to identify subsets of B cells, 
how they contribute to pathology or protection from disease, 
and their susceptibility to different methods of therapeutic 
intervention.
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